News

Boehringer said that the new findings fully support the convincing results from the RE-LY trial and show that AF patients with previous stroke or transient ischemic attack (TIA)

Santabarbara joins Infinity following five years with PharmaMar, where he most recently led the development and approval of Yondelis (trabectedin). Prior to PharmaMar, he served as vice president

Williams joins Aqua following an executive director position at Watson Pharmaceuticals, where he was responsible for brand and biologics business development since 2004. In that role, Williams developed

Hamilton will be responsible for guiding the company’s clinical programs, including the PICASSO 3 trial, an international, randomised, double-blinded, placebo-controlled trial of palifosfamide and doxorubicin in patients with

As per the terms of this collaboration, Kollmann is expected to use Advaxis proprietary Listeria vaccine vectors for the development of novel infectious disease applications, and employ a

Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer. The company has operations in London, UK and Cambridge, MA. Antisoma,

The randomised, double-blind, placebo-controlled, multi-center Phase II clinical trial is expected to begin enrolling patients before the end of 2010 and is part of a collaboration between Athersys

SDIX has posted a net loss of $29,000 for the third quarter 2010, or $0 loss per diluted share, compared to net loss of $291,000 or $0.01 loss

The clinical research program will be led by Jeffrey Stout, MusclePharm’s scientific advisor, who will study the effects of MusclePharm’s products on high-intensity interval training, on aerobic and